MP35-04 TESTOSTERONE REPLACEMENT THERAPY: PATIENT REPORTED PREFERENCES

Abstract

You have accessJournal of UrologyCME1 May 2022MP35-04 TESTOSTERONE REPLACEMENT THERAPY: PATIENT REPORTED PREFERENCES Charles Loeb, Jake Miller, Douglas Schneider, and Faysal Yafi Charles LoebCharles Loeb More articles by this author , Jake MillerJake Miller More articles by this author , Douglas SchneiderDouglas Schneider More articles by this author , and Faysal YafiFaysal Yafi More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002589.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Men with symptomatic hypogonadism can be treated with testosterone replacement therapy (TRT) in a variety of methods. Multiple factors including cost, efficacy, adverse effects, and mechanism and frequency of administration must be considered when prescribing to promote maximum patient satisfaction and clinical results. We aim to determine the attitudes, opinions and preferences of men regarding their TRT and the factors that influence these preferences. METHODS: An anonymous online survey was distributed to 783 men currently on TRT in a single men’s health clinic. Men answered questions on demographics, comorbidities, social history and validated questionnaires Sexual Health Inventory for Men (SHIM) and Androgen Deficiency in the Aging Male (ADAM). They were asked about prior and current methods and overall satisfaction with current TRT. Preferences regarding administration, cost, effectiveness and adverse effects were assessed qualitatively and in head-to-head comparisons. RESULTS: The median age of 140 respondents was 65 years (32–87). The most commonly reported method of administration was intramuscular injection (A). Overall satisfaction with current therapy was reported as very or somewhat satisfied in the majority of respondents (B). The most commonly preferred methods of administration were intramuscular injection (22%), swallowed pill (18%), subcutaneous auto-injector (13%), topical ointment (13%), nasal spray (12%), dissolved oral solution (8%) and skin patch (5%) (C). The most commonly preferred injection method was self-administration at home (D). The most preferred potential benefit was improved sexual function (E). The most concerning potential side effects were cardiac related (F). Higher satisfaction was associated with use of injection (OR 7.21, p=0.011), pellet (12.58, p=0.011), autoinjector (13.50, p=0.006), and sexually active patients (3.30, p=0.002). Lower satisfaction was associated with older age (OR 0.94, p=0.012) and positive ADAM score (0.04, p=0.003). CONCLUSIONS: The majority of respondents were satisfied overall with their current therapy. The preferred TRT option was self-injection therapy at home. Treatment efficacy and fewest side effects were the most important considerations for patients on TRT. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e588 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Charles Loeb More articles by this author Jake Miller More articles by this author Douglas Schneider More articles by this author Faysal Yafi More articles by this author Expand All Advertisement PDF DownloadLoading ...